Page 23 - Bharat Biotech

Drug controller hints vaccine approval will make it a 'happy new year'

V G Somani's statement comes even as subject expert committee is set to meet on Jan 1 to consider three emergency-use authorisation applications

India's Covid vaccine hope rolls over to 2021; panel to meet again on Jan 1

Sources close to the development said the expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine

CDSCO panel to reconvene on Jan 1 to consider vaccine's emergency use

An expert panel in the Central Drugs Standard Control Organisation that met on Wednesday to consider emergency use authorisation applications will reconvene on Jan 1 to deliberate on the matter.

Drug regulator to meet again on Jan 1 to discuss AstraZeneca vaccine

India is also considering emergency-use authorisation applications for vaccines made by Pfizer Inc with Germany's BioNTech, and by India's Bharat Biotech

Covaxin can deal with new Covid strains too: Bharat Biotech chairman

Bharat Biotech's Chairman Krishna Ella said on Tuesday that its vaccine candidate, Covaxin, will be effective in dealing with new strains of coronavirus.

Gujarat: Over 750 volunteers get Covaxin first dose in phase-3 trial

None of them have experienced any side effects so far, a senior doctor said on Sunday

Vice President discusses status of indigenous vaccine against Covid-19

Bharat Biotech Chairman and Managing Director Dr Krishna Ella and Joint Managing Director Suchitra Ella called on the Vice President M Venkaiah Naidu in Hyderabad

Bharat Biotech's top brass calls on Vice President Venkaiah Naidu

Bharat Biotech's top brass on Friday called on Vice President M Venkaiah Naidu in Hyderabad

Biotech's Covaxin shows good results in clinical trials: Research paper

Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials

People who are infected should also take vaccine: Bharat Biotech Chairman

People who are infected should also take a vaccine,and India is well prepared regarding the logistics for the vaccine distribution,Bharat BiotechChairman & MD Krishna Ella said on Wednesday. He was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industrybody CII. For the peoplewho are infected,shouldthey take a vaccine, "the answeris yes", becausethey may not have a goodT cells response..., Ella said. Talking about the company's efficacy trials of its COVID-19 vaccine, he said that for the efficacy trials the company has taken 24 centres all over the country so that it has tier I ,tierIIand tier III cities to capture the efficacy in a better way. On the distribution of vaccines in India, he said India is well prepared for that and Indian immunisation system is very robust, Ella said. Speaking at the session, Biocon ChairpersonKiran Mazumdar Shaw said, "We have to ensure we have a sense of .

'It's nightmarish': Uphill task as Bharat Biotech gears for vaccine rollout

Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year

Bharat Biotech halfway through in one of country's largest phase-3 trials

Pfizer yet to submit data to regulator while Serum Institute has provided all additional information for emergency use authorisation

Ocugen to co-develop Bharat Biotech's Covid-19 vaccine candidate for US

Drug developer Ocugen said it had partnered with Bharat Biotech to co-develop the India-based company's Covid-19 vaccine candidate for the US market

Bharat Biotech recruits 13,000 volunteers for Covaxin Phase 3 trials

Bharat Biotech announced successful recruitment of 13,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase III clinical trial of its Covid vaccine Covaxin

Inactivated Covid vaccine safest with lesser bad reactions: Bharat Biotech

Bharat Biotech has claimed that amongst all the vaccine platforms such as an mRNA-based vaccine and DNA-based vaccine, the inactivated vaccines being developed by it for Covid-19 are safest

Paediatric coronavirus vaccine work may begin in India by mid of 2021

Bharat Biotech is testing its whole virus inactivated vaccine, a tech in use for decades, on subjects aged 12 years and above

Covaxin facing shortage of volunteers for phase 3 trials, says AIIMS

The Phase III clinical trial for Bharat Biotech's vaccine candidate Covaxin is witnessing a shortage of volunteer participation, with a high refusal rate of 70% to 80%, a senior AIIMS doctor said

Covaxin's phase 1 trial data shows robust response: Bharat Biotech

Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies

States told to estimate and strengthen cold chain for vaccine: Health secy

In all, 29,000 cold chain points, 240 walk-in coolers, 70 walk-in freezers, 45,000 ice-lined refrigerators, 41,000 deep freezers and 300 solar refrigerators are to be used

Seven important Coronavirus vaccine updates that you need to know

Listen to the podcast to know about the current status of the Covid-19 vaccine in India and other parts of the world